IMU-131
- Generic Name
- IMU-131
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Phase 2
Terminated
- Conditions
- Gastric CancerStomach AdenocarcinomaStomach CancerGastric AdenocarcinomaCancer of StomachGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 7
- Registration Number
- NCT05311176
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan City, Taiwan
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Phase 1
Completed
- Conditions
- Gastrointestinal NeoplasmsAdenocarcinoma
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 64
- Registration Number
- NCT02795988
- Locations
- 🇺🇦
ARENSIA Exploratory Medicine LLC, Kapitanivka, Ukraine
🇮🇳City Cancer Center, Vijayawada, Andhra Pradesh, India
🇮🇳North East Cancer Hospital and Research Institute, Guwahati, Assam, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath